Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6140 · 6 trials · 7 indications
Maximum Concentration (Cmax), Time to reach maximum (peak) plasma concentration (tmax), Terminal plasma half-life (t½), Area under the plasma concentration-time curve from time zero to time t (AUC(0-t)),Area under the plasma concentration-time curve (AUC), Apparent total clearance of the drug from plasma after oral administration (CL/F), Apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F), Mean residence time (MRT), and AUC and Cmax ratios of AR-C124910XX to AZD6140,
| Arm | Type | Description |
|---|---|---|
| AZD6140 | EXPERIMENTAL | single administration of 90 mg dose of AZD6140 |
| 1 | EXPERIMENTAL | Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder |
| 2 | PLACEBO_COMPARATOR | Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder |
| Name | Type | Description |
|---|---|---|
| AZD6140 | DRUG | tablet |
| Placebo | DRUG | - |
| Placebo to match AZD6140 | DRUG | Oral tablets taken bid for 5 days |
| Levonorgestrel and Ethinyl Estradiol (Nordette®) | DRUG | 1 tablet taken by mouth once a day for 28 days per cycle |
Inclusion Criteria: * Healthy male subject aged between 20 to 45 years inclusive * Body mass index (BMI=weight/height2) between 18.0 to 27.0 kg/m2 inclusive * Body weight between 50.0 to 85.0 kg inclusive Provision of written informed consent Exclusion Criteria: * Clinically significant abnormali...
AZD6140 is an investigational small molecule being studied for use in gout, renal impairment, and healthy volunteer settings, including pharmacokinetics and blood flow speed. It is in Phase 1 clinical development for these indications. The drug is being developed by AstraZeneca PLC.
AZD6140 is a small molecule in the cardiovascular therapeutic area. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its effects on uric acid levels and other cardiovascular-related parameters.
AZD6140 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting Phase 1 clinical trials to evaluate the drug's safety and pharmacokinetics in various patient populations.
AZD6140 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. All completed trials for AZD6140 are Phase 1 studies, and the drug is not yet available for clinical use outside of research settings.
AZD6140 has been studied in several completed Phase 1 trials. These include NCT00685906, an oral contraceptive interaction study in healthy women; NCT00733265, a study in patients with renal impairment and healthy volunteers; NCT00738842, a uric acid study in healthy males; and NCT01588626, a pharmacokinetic study in healthy Japanese males.
AZD6140 is the investigational code name for the drug that is also known as ticagrelor. Ticagrelor is an antiplatelet medication that has been studied in cardiovascular conditions. In the clinical trials listed, AZD6140 is being evaluated for its effects on uric acid and other parameters.